Proteins and Peptides

23 Apr 2019 Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid
12 Apr 2019 89bio Announces Preclinical Data That Demonstrate Potential Utility of BIO89-100 for Treatment of NASH
09 Apr 2019 PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge
08 Apr 2019 Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
03 Apr 2019 Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol
03 Apr 2019 Sandoz resubmits biosimilar pegfilgrastim application to US FDA
30 Mar 2019 Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team
26 Mar 2019 Promedior Received Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis
26 Mar 2019 Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Acute Antibody Mediated Rejection in Kidney Transplantation
26 Mar 2019 Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019
26 Mar 2019 Therachon Presents Data from Preclinical and Phase I clinical Studies of Apraglutide for the Treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference
24 Mar 2019 Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO
21 Mar 2019 OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial
21 Mar 2019 AB2 Bio Announces Readiness for Recruitment in Pivotal Phase 3 Trial of Tadekinig Alfa, a Novel Human Recombinant Interleukin-18 Binding Protein, in Children with Genetic Diagnosis of NLRC4-MAS Mutation or XIAP Deficiency, with Amended Design in the U.S.
20 Mar 2019 Arch Biopartners Receives Approval to Perform Phase I Clinical Trial for Metablok in Australia
20 Mar 2019 Novo Nordisk files oral semaglutide for US regulatory approval of glycaemic control, as well as for CV risk reduction for oral semaglutide and Ozempic
19 Mar 2019 Alkahest Doses First Subject in Phase 2 Clinical Trial of Lead Candidate in Patients with Severe Alzheimer's Disease
19 Mar 2019 Cytovation Initiates Clinical Development Programme With CyPep-1, a First-in-class Lytic Agent for Tumor Immunotherapy
19 Mar 2019 BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
15 Mar 2019 Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia
15 Mar 2019 ImmunogenX Initiates Phase 2 Trial for its Lead Therapeutic and Diagnostic Candidates Latiglutenase and CypCel
15 Mar 2019 Spectrum Pharmaceuticals Provides BLA Filing Update for ROLONTIS® (eflapegrastim)
08 Mar 2019 FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity
07 Mar 2019 Baxter Announces U.S. FDA Approval and Launch of Ready-to-Use Cardiovascular Medicine Eptifibatide
06 Mar 2019 Zealand Pharma doses first patient in Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top